<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cefoxitin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01331</strong>&#160; (EXPT00897)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01331/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01331/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01331.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01331.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01331.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01331.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01331.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01331">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cefoctin</td><td>Teva</td></tr><tr><td>Cenomicin</td><td>Daiichi-Seiyaku</td></tr><tr><td>Mefoxin</td><td>Merck</td></tr><tr><td>Mefoxitin</td><td>Merck</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/cephalosporins">Cephalosporins</a></li></ul></td></tr><tr><th>CAS number</th><td>35607-66-0</td></tr><tr><th>Weight</th><td>Average: 427.452<br>Monoisotopic: 427.050791293</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>17</sub>N<sub>3</sub>O<sub>7</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>WZOZEZRFJCJXNZ-ZBFHGGJFSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Cephalosporins</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; 1,3-Thiazines; Thiophenes; Tertiary Carboxylic Acid Amides; Azetidines; Secondary Carboxylic Acid Amides; Carbamic Acids and Derivatives; Tertiary Amines; Hemiaminals; Ethers; Enamines; Carboxylic Acids; Thioethers; Polyamines; Aminals; Enolates</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; meta-thiazine; thiophene; tertiary carboxylic acid amide; tertiary amine; azetidine; hemiaminal; carbamic acid derivative; secondary carboxylic acid amide; carboxamide group; polyamine; thioether; ether; enamine; carboxylic acid; enolate; aminal; carboxylic acid derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moeity or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of serious infections caused by susceptible strains microorganisms.</td></tr><tr><th>Pharmacodynamics</th><td>Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.</td></tr><tr><th>Mechanism of action</th><td>The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).</p></td></tr><tr><th>Route of elimination</th><td>Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.</td></tr><tr><th>Half life</th><td>The half-life after an intravenous dose is 41 to 59 minutes. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.7203</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9952</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8198</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8831</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9715</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9085</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8655</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8241</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5389</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.786</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8214</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8642</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7954</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9312</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8753</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6912
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9329
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.979
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.6623 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9951
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8518
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Acs dobfar spa</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Hikma farmaceutica (portugal) sa</li>
<li>Orchid healthcare</li>
<li>B braun medical inc</li>
<li>Bioniche pharma usa llc</li>
<li>Merck and co inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.bbraun.com">B. Braun Melsungen AG</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bionichepharmausa.com">Bioniche Pharma</a></li>
<li><a href="http://www.hanford.com">GC Hanford Manufacturing Co.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.orchidpharma.com">Orchid Healthcare</a></li>
<li><a href="http://www.sagentpharma.com">Sagent Pharmaceuticals</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intramuscular</td><td></td></tr><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The cephalosporin, cefoxitin, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The cephalosporin, cefoxitin, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01172">Kanamycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00994">Neomycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Probenecid may increase the serum level of cefoxitin.</td></tr><tr><td><a href="/drugs/DB01082">Streptomycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>